Navigating PET Scans for Alzheimer’s Diagnosis: A Practical Guide for Caregivers and Early-Stage Patients

PET scans can be a powerful tool to confirm Alzheimer’s pathology, especially when standard tests like MRI or cognitive exams are unclear. But they’re expensive and not always covered by insurance, which can feel like a roadblock. This guide walks you through what PET scans are, why they matter, and concrete steps to access them—even when coverage is limited. You’ll find real words to say to doctors, how to explore financial help, and what to expect during the process, so you can make informed decisions without feeling lost.

Key points

• PET scans (FDG-PET and amyloid PET) can clarify an Alzheimer’s diagnosis when standard tests are inconclusive, especially in early-stage or atypical cases.
• Medicare covers FDG-PET for diagnostic uncertainty but generally does not cover amyloid PET; out-of-pocket costs can be high.
• Clinical trials and research studies are a viable way to access free PET scans—search ClinicalTrials.gov and use the Alzheimer’s Association TrialMatch.
• Prepare the person with dementia for the scan with simple explanations and practice to reduce anxiety and ensure a successful procedure.
• Always discuss the emotional and practical implications of a positive result with your clinician before proceeding.
• Explore alternatives like the PrecivityAD blood test or lumbar puncture, which may be cheaper or more accessible.

What PET Scans Reveal and Why They’re Used

PET scans for Alzheimer’s come in two main types: FDG-PET and amyloid PET. An FDG-PET scan measures how well brain cells are using glucose (sugar) for energy. In Alzheimer’s, certain brain regions show reduced glucose use, creating a pattern that can suggest the disease. An amyloid PET scan goes a step further by detecting amyloid plaques—sticky protein clumps that are a hallmark of Alzheimer’s pathology. As one neurologist explains, an amyloid PET scan is ‘a very, very precise way of trying to establish whether there is Alzheimer amyloid pathology present or not’ (source: PCA Lecture Series). These scans are not routine; they’re typically ordered when a diagnosis remains uncertain after a thorough history, cognitive testing, and a standard brain MRI. For example, in early-stage or atypical forms like posterior cortical atrophy (PCA), the brain MRI may look nearly normal, making it ‘almost impossible to tell that there’s anything unusual going on’ (source: PCA Lecture Series). In such cases, a PET scan can provide clarity that changes the care plan.

The Coverage Gap: Medicare and Out-of-Pocket Costs

Access to PET scans is complicated by insurance coverage. For people with Medicare, an FDG-PET scan may be covered if it’s deemed medically necessary—for instance, when the diagnosis is still in doubt after standard evaluation. However, amyloid PET scans are generally not covered by Medicare for routine Alzheimer’s diagnosis. As one source notes, ‘amyloid PET scans are not covered by [Medicare]’ (source: PCA Lecture Series). For those under 65 who are not yet Medicare-eligible, both types of PET scans would typically need to be paid for out of pocket, which can cost several thousand dollars. This financial barrier can feel overwhelming, but there are pathways to explore—such as clinical trials, research studies, or negotiating with imaging centers. The key is to understand that coverage depends on your specific situation, your doctor’s documentation, and the type of scan ordered.

Why a PET Scan Might Be Worth Pursuing

Even with the cost and hassle, a PET scan can be invaluable for early-stage patients and their families. An accurate diagnosis helps rule out other causes of cognitive decline—like stroke, vitamin deficiencies, or other dementias—that might be treatable. It also opens the door to targeted treatments, such as anti-amyloid therapies (like lecanemab or donanemab), which require confirmation of amyloid plaques before use. For caregivers, knowing the exact diagnosis can reduce uncertainty and anxiety, allowing you to plan for the future with more confidence. As one caregiver advocate put it, getting a clear diagnosis ‘helps in not only understanding what is going on but how to help the person’ (source: Teepa Snow’s Positive Approach to Care). However, it’s important to weigh the benefits against the emotional impact: a positive amyloid PET result can cause significant anxiety, and there’s no guaranteed way to prevent or delay Alzheimer’s progression. Discuss these trade-offs with your clinician.

General caregiving information, not medical advice. Check medications and major care changes with your clinician.

Discuss with your clinician

Ask your doctor: ‘Given my family history and symptoms, what is the likelihood that a PET scan will change my treatment plan? Are there risks from the radiation or the contrast agent used in the scan?’

Discuss the potential psychological impact: ‘If the scan is positive for amyloid, how will we manage the emotional fallout? Do you have a counselor or support group you can recommend?’

Inquire about alternative biomarkers: ‘Would a spinal tap (lumbar puncture) for amyloid and tau proteins be as accurate as a PET scan? Is it covered by my insurance? What are the risks?’

Ask about the PrecivityAD blood test: ‘Is this test available and appropriate for me? How does its accuracy compare to a PET scan? Would a positive result still require a PET scan for confirmation?’

If you’re considering anti-amyloid therapy, ask: ‘Do I need a PET scan to qualify for treatment? What are the criteria for these medications, and how do I access them?’

Related guides

• Recognizing and responding to early frontal-lobe behavior changes
• The Real Costs of Dementia Care: What Medicare, Medicaid, and Insurance Actually Cover (and What You'll Pay Yourself)
• Navigating Clinical Trial Recruitment and Making Informed Research Decisions
• Understanding the New FDA-Approved Blood Test for Alzheimer’s (Lumipulse pTau217)
• sharing dementia care costs among family members
• Helping Your Loved One Stay Calm During a PET or FDG Brain Scan
• Posterior Cortical Atrophy (PCA): The Visual-First Dementia — A Caregiver's Guide to What's Happening
• Communication changes to reduce caregiver stress
• How to Submit Public Comment on Medicare Coverage of Anti-Amyloid Alzheimer's Drugs
• Benefits of home care for dementia

Sources

• NICE
• PubMed
• AAFP
• Alzheimer's Association
• Mayo Clinic
• newsnetwork.mayoclinic.org
• Dementia Careblazers
• The Dementia Doctor
• PCA LECTURE SERIES with host Jamie Talan
• Alzheimer's Proof